Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.25 ▼ -0.04
(-1.22%)
MKT CAP: $120.8M • VOL: 103.0K
52W L $3 52W H $15
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$4
MEAN
$4
HIGH
$4
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ARMP TAPE
ARMP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $3.93 | $3.74 | 2025-02-14 | $2.96 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $4.09 | $3.83 | 2025-02-06 | $3.05 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $3.70 | $3.58 | 2025-01-29 | $3.12 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.31 | — | 2025-01-17 | $3.19 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $2.86 | $3.09 | 2025-01-09 | $2.89 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $3.87 | $3.38 | 2024-12-18 | $2.83 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $3.15 | $3.28 | 2024-12-04 | $3.02 | -4.3% | 48% | C |